2024-513931-26-00招募中2 期
Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC trial
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 21
- 试验地点
- 7
- 主要终点
- Pathologic complete response (pCR), defined as complete histological regression with no available tumor cells (yT0N0) in the intention-to-treat population
研究概览
简要总结
The main objective of the trial is to evaluate the activity, in terms of pathologic complete response, of the addition of temozolomide to standard concurrent capecitabine-based chemoradiation, in moleculary selected patient with low-risk locally advance rectal cancer molecularly selected formicrosetellite stability, MGMT negative IHC and MGMT promoter methylation.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Written informed consent to study procedures
- •No evidence of enlarged lateral pelvic clinically positive lymph node (> 1 cm)
- •No evidence of extramural vascular invasion (EMVI)
- •No evidence of metastatic disease by CT scan of the chest and abdomen and total body FDG PET/CT scan
- •No clear indication of involvement of the pelvic side walls by imagin
- •Tumor must be amenable to curative resection (curative resection can include pelvic exenteration)
- •No prior infiltrating tumors of the rectum
- •Hematopoietic: absolute neutrophil count =1500/mm3; platelet count = 100,000/mm3; haemoglobin level = 10 g/dL
- •Hepatic total bilirubin =1.5 time upper limit of normal (ULN); alkaline phosphatase = 2 times ULN; AST and ALT = 2.5 times ULN Serum creatinine = 1.5 × ULN or renal creatinine clearance = 50 mL/min according to the Cockcroft-Gault formula (or local institutional standard methods)
- •Age = 18 years
- •ECOG PS 0-1
- •Life expectancy of at least 5 years (excluding diagnosis of cancer)
- •Histologically confirmed diagnosis of rectal adenocarcinoma, with centrally confirmed mismatch repair proficiency by multiplex polymerase chain reaction (PCR), lack of MGMT expression by immunohistochemistry and MGMT promoter methylation by pyrosequencing
- •Locally advanced, resectable disease defined by the presence of at least one of the following features
- •Distal tumor margin at <15 cm from the anal verge
- •cT3N0 or cT1-3N1(with the definition of a clinically positive lymph node being any node = 1 cm)
- •Less than four lymph nodes in the mesorectum showing morphological signs on MRI indicating metastatic disease
排除标准
- •Dihydropyrimidine dehydrogenase (DPD) deficiency
- •Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies
- •Pregnant or lactating women
- •Previous pelvic RT
- •Any of the following in the 6 months prior to treatment start: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure (= New York Heart Association Classification Class II), cerebrovascular accident/stroke, transient ischemic attack, serious cardiac arrhythmia requiring medication or symptomatic pulmonary embolism
- •Uncontrolled coagulopathy
- •Active infection requiring systemic therapy
- •Infection with human immunodeficiency virus (HIV) plus CD4 cells <200/mm3 or AIDSdefining conditions despite HAART
- •Lack of upper gastrointestinal tract integrity or malabsorption syndrome; immune colitis; active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic)
- •Patients with prior malignancies (with the exception of rectal cancer), including invasive colon cancer, are eligible provided they have been disease-free for = 3 years and are deemed by their physician to be at low risk for recurrence (patients with effectively treated squamous cell or basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum are eligible even if diagnosed less than 3 years before study enrollment)
- •Other severe acute or chronic medical conditions including immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
结局指标
主要结局
Pathologic complete response (pCR), defined as complete histological regression with no available tumor cells (yT0N0) in the intention-to-treat population
Pathologic complete response (pCR), defined as complete histological regression with no available tumor cells (yT0N0) in the intention-to-treat population
次要结局
- R0 resection rate (defined as the rate of microscopically margin-negative resections)
- Sphincter preservation rate (defined as the percentage of patients with preserved anorectal sphincter after surgery)
- overall survival
- Tumor downstaging rate (defined as the rate of reduction in the stage of the tumor as a result of therapy, from a more to a less threatening stage)
- Local recurrence rate (defined as the rate of detectable local disease at follow-up after study treatment completion)
- disease-free survival
研究者
Filippo Pietrantonio
Scientific
Fondazione IRCCS Istituto Nazionale Dei Tumori
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit ElderlyRectal Neoplasms MalignantNCT02992886Chinese Academy of Medical Sciences68
进行中（未招募）
1 期
Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC triallocally advanced rectal cancer (LARC)MedDRA version: 20.0Level: HLTClassification code: 10010023Term: Colorectal neoplasms malignant Class: 10029104CTIS2024-513931-26-00Fondazione IRCCS Istituto Nazionale Dei Tumori21
进行中（未招募）
1 期
Study on the association of radiotherapy with capecitabine and temozolomide followed by surgery in patients with locally advanced rectal cancerEUCTR2021-002325-18-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI21
Unknown
2 期
Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal CancerRectal NeoplasmNeoadjuvant TherapyNCT00506623National Cancer Center, Korea48
招募中
2 期
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic CancerPancreas AdenocarcinomaResectable Pancreatic CancerNCT03492671Loma Linda University30